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  HCD OT HCD IT EThcD OT EThcD IT HCD nl EThcD IT HCD nl ETcaD IT HCD OT nl EThcD IT HCD OT nl ETcaD IT 
MS1                
Orbitrap Resolution 60K 120K 60K 120K 120k 120k 60k 60k 
RF Lens 60 60 60 60 60 60 60 60 
Scan range (m/z) 350-2000 350-2000 350-2000 350-2000 350-2000 350-2000 350-2000 350-2000 
AGC 2.00E+05 2.00E+05 2.00E+05 2.00E+05 2.00E+05 2.00E+05 2.00E+05 2.00E+05 
Injection time 50 ms 50 ms 50 ms 50 ms 50 ms 50 ms 50 ms 50 ms 
MIPS Peptide Peptide Peptide Peptide Peptide Peptide Peptide Peptide 
Intensity 5.00E+04 5.00E+03 5.00E+04 5.00E+03 5.00E+03 5.00E+03 5.00E+04 5.00E+04 
Charge states 2+ to 5+ 2+ to 5+ 2+ to 5+ 2+ to 5+ 2+ to 5+ 2+ to 5+ 2+ to 5+ 2+ to 5+ 
Dynamic exclusion 
60 s/ exclude 
isotopes 
60 s/exclude 
isotopes 
60 s/ exclude 
isotopes 
60 s/exclude 
isotopes 
60 s/exclude 
isotopes 
60 s/exclude 
isotopes 
60 s/exclude isotopes 60 s/exclude isotopes 
Cycle time 3 s 3 s 3 s 3 s 3 s 3 s 3 s 3 s 
MS2 
  
 
     
Isolation mode Quadrupole Quadrupole Quadrupole Quadrupole Quadrupole Quadrupole Quadrupole Quadrupole 
Isolation window 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 
NCE 32 32 
Cal. ETD reaction 
time, HCD 25% 
Cal. ETD reaction 
time, HCD 25% 
32 32 32 32 
Detector Orbitrap Ion Trap Orbitrap Ion Trap Ion Trap Ion Trap Orbitrap Orbitrap 
Resolution 30k Rapid 30k Rapid Rapid Rapid 30k 30k 
First mass 110 m/z 110 m/z 110 m/z 110 m/z 110 m/z 110 m/z 110 m/z 110 m/z 
Target value 5.00E+04 1.00E+04 5.00E+04 1.00E+04 1.00E+04 1.00E+04 5.00E+04 5.00E+04 
Max. injection time 100 ms 35 ms 70 ms 50 ms 35 ms 35 ms 100 ms 100 ms 
Data Type Profile Centroid Profile Centroid Centroid Centroid Profile Profile 
Neutral Loss Trigger                
Targeted trigger (amu) 
    
 
  M=97.9763, M=80 M=97.9763, M=80 
M=97.9763,  
M=80 
M=97.9763,  
M=80 
Mass tolerance 
  
 
 
0.5 m/z 0.5 m/z 20 ppm 20 ppm 
Isolation mode 
  
 
 
Quadrupole Quadrupole Quadrupole Quadrupole 
Isolation width 
  
 
 
1.6 1.6 1.6 1.6 
Activation type 
  
 
 
ETD cal. 
parameters 
ETD cal. 
parameters 
ETD cal. parameters ETD cal. parameters 
SA Collision energy 
  
 
 
EThcD 25% ETcaD 15% EThcD 25% ETcaD 15% 
Detector  
  
 
 
Ion Trap Ion Trap Ion Trap Ion Trap 
Scan rate 
  
 
 
Rapid Rapid Rapid Rapid 
First mass 
  
 
 
110 m/z 110 m/z 110 m/z 110 m/z 
AGC 
  
 
 
1.00E+04 1.00E+04 1.00E+04 1.00E+04 
Max injection time     50 ms 50 ms 50 ms 50 ms 
Table S1. Orbitrap Fusion Tribrid MS acquisition parameters for the eight methods assessed. Cal. ETD refers to the fact that the ETD reaction time 
was calibrated according to precursor ion charge state using angiotensin. AGC: automatic gain control; IT: Ion trap; MIPS: monoisotopic precursor selection; 
NCE: normalised collision energy; NL: Neutral loss; OT: Orbitrap; SA: Supplemental activation. 
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Search Engine    HCD OT HCD IT EThcD OT EThcD IT HCD OT nl EThcD HCD OT nl ETcaD HCD IT nl EThcD HCD IT nl ETcaD 
Andromeda (1% 
FDR) 
# PSM
a
 705 ± 4 984 ±16 407 ± 18 515 ± 88 625 ± 194 650 ± 30 838 ± 37 745 ± 36 
  # unique phosphopeptides  153 160 146 153 156 154 154 155 
  # phosphosites 167 173 160 167 170 168 168 170 
  
# phosphosites correctly 
localised with PTM-score  
153 155 155 159 152 154 147 150 
 
% phosphosites correctly 
localised with PTM-score   
92% 90% 97% 95% 89% 92% 88% 88% 
Andromeda (1% 
FDR, no score filter) 
# PSM
a
 743 ± 25  987  ± 25 423 ± 15 540  ± 82 640  ± 210 668  ± 31 848  ± 45 744  ± 28 
  # unique phosphopeptides  160 163 151 152 155 159 155 155 
  # phosphosites 175 178 165 166 170 174 169 169 
  
# phosphosites correctly 
localised with PTM-score  
160 154 158 156 149 159 151 152 
 
% phosphosites correctly 
localised with PTM-score   
91% 87% 96% 94% 88% 91% 89% 90% 
 
Table S2. Evaluation of Andromeda score cut-off using synthetic phosphopeptides. For each of the eight Orbitrap Fusion MS acquisition methods (Table 
1, Table S1) the number of peptide spectrum matches (PSMs) are presented (n = two technical replicates), together with the number of unique peptides (out of a total of 
171) and phosphosites (of 185 total), as well as the number and percentage of correctly localized phosphosite using Andromeda with PTM-score (bottom) with either default 
settings, invoking a score cut off of 40 for modified peptides (top), or with this score filter removed (bottom).  
a
Mean values are presented ± S.D. 
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Figure S1. Acquisition method-specific phosphosite localization. Number of correctly assigned (green) and incorrectly assigned (white) 
phosphosites from the synthetic phosphopeptide library for each of the eight MS acquisition methods using either Andromeda or MASCOT 
(Table 1; Table S1).
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Figure S2. Overlap between technical replicates processed using Andromeda. U2OS phosphopeptide enriched cell lysate was analysed in 
duplicate using each of six Orbitrap Fusion MS acquisition methods as indicated. Venn diagrams present the overlap in the number of 
identified phosphopeptides between replicate analyses for each of the methods. See Table S1 for full details of MS methods. 
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Figure S3. Overlap between technical replicates processed using Mascot. U2OS phosphopeptide enriched cell lysate was analysed in duplicate 
using each of six Orbitrap Fusion MS acquisition methods as indicated in duplicate. Venn diagrams present the overlap in the number of 
identified phosphopeptides between replicate analyses for each of the methods. See Table S1 for full details of MS methods.  
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Figure S4. Distribution of phosphosite localisation scores for either PTM-score (A) or ptmRS (B) from cell lysate-derived phosphopeptides 
analysed using either HCD OT (red), HCD IT (blue), EThcD OT (green) or EThcD IT (purple). Dotted lines represent the value equivalent to 1% 
FLR (0.7% FLR for EThcD OT). Insets depict the complete score distribution for each site localisation algorithm. 
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Figure S5. Phosphosite localisation confidence with Andromeda/PTM-score. Percent correctly site localised phosphopeptides (FLR ≤1%, 
green) or site ambiguous (FLR >1%, white/grey) phosphopeptides is presented for (A) all identified phosphorylation sites; (B) singly 
phosphorylated peptides; (C) doubly phosphorylated peptides; (D) triply phosphorylated peptides.  
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Figure S6. Phosphosite localisation confidence with MASCOT/ptmRS. Percent correctly site localised phosphopeptides (FLR ≤1%, green) or 
site ambiguous (FLR >1%, white/grey) phosphopeptides is presented for (A) all identified phosphorylation sites; (B) singly phosphorylated 
peptides; (C) doubly phosphorylated peptides; (D) triply phosphorylated peptides  
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Figure S7. Phosphosite localisation confidence as 
determined using Andromeda/PTM-score, as a function 
of prevalence of common putative phosphorylated 
residues. Numbers (left) and percentage (right) of correctly 
site localised phosphopeptides (FLR ≤1%, green) or site 
ambiguous (FLR >1%, white) phosphopeptides are presented as 
a function of the number of Ser (S), Thr (T) or Tyr (residues) 
within the peptide for each of the six MS acquisition methods: 
(A) HCD OT; (B) HCD IT; (C) EThcD OT; (D) EThcD IT; (E) HCD OT 
nl EThcD IT; (F) HCD IT nl EThCD IT. 
Ferries et al.,                                                 Supplementary Information 
 S11 
 
Figure S7 continued. Phosphosite localisation confidence as 
determined using Andromeda/PTM-score, as a function of 
prevalence of common putative phosphorylated residues. 
 Numbers (left) and percentage (right) of correctly site localised 
phosphopeptides (FLR ≤1%, green) or site ambiguous (FLR >1%, 
white) phosphopeptides are presented as a function of the number 
of Ser (S), Thr (T) or Tyr (residues) within the peptide for each of 
the six MS acquisition methods: (A) HCD OT; (B) HCD IT; (C) EThcD 
OT; (D) EThcD IT; (E) HCD OT nl EThcD IT; (F) HCD IT nl EThCD IT. 
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Figure S8. Phosphosite localisation confidence as 
determined using MASCOT/ ptmRS, as a 
function of prevalence of common putative 
phosphorylated residues. 
 Numbers (left) and percentage (right) of correctly site 
localised phosphopeptides (FLR ≤1%, green) or site 
ambiguous (FLR >1%, white) phosphopeptides are 
presented as a function of the number of Ser (S), Thr 
(T) or Tyr (residues) within the peptide for each of the 
six MS acquisition methods: (A) HCD OT; (B) HCD IT; 
(C) EThcD OT; (D) EThcD IT; (E) HCD OT nl EThcD IT; (F) 
HCD IT nl EThCD IT. 
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Figure S8 continued. Phosphosite 
localisation confidence as determined using 
MASCOT/ ptmRS, as a function of 
prevalence of common putative 
phosphorylated residues. 
 Numbers (left) and percentage (right) of correctly 
site localised phosphopeptides (FLR ≤1%, green) 
or site ambiguous (FLR >1%, white) 
phosphopeptides are presented as a function of 
the number of Ser (S), Thr (T) or Tyr (residues) 
within the peptide for each of the six MS 
acquisition methods: (A) HCD OT; (B) HCD IT; (C) 
EThcD OT; (D) EThcD IT; (E) HCD OT nl EThcD IT; 
(F) HCD IT nl EThCD IT. 
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Figure S9. Phosphosite 
localisation determined 
using Andromeda/PTM-
score, as a function of 
peptide ion charge state. 
Numbers (A) and 
percentage (B) of correctly 
site localised phospho-
peptides (FLR ≤1%, green) 
or site ambiguous (>1%, 
white) phosphopeptides are 
presented as a function 
precursor ion charge state 
for each of the six MS 
acquisition methods. 
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Figure S10. Phosphosite 
localisation determined 
using MASCOT/ptmRS, as 
a function of peptide ion 
charge state. Numbers (A) 
and percentage (B) of 
correctly site localised 
phosphopeptides (FLR ≤1%, 
green) or site ambiguous 
(>1%, white) phospho-
peptides are presented as a 
function precursor ion 
charge state for each of the 
six MS acquisition methods. 
 
